title: Effects of halofuginone on fibrosis formation secondary to experimentally induced subglottic trauma.
abstract: OBJECTIVE
  The aim of the study was to assess the antifibrotic effect of systemically applied halofuginone after subglottic injury.
  
  
  METHODS
  After standardized trauma to subglottic area, rats were divided into two groups: a study group that received treatment and a control group that did not. The rats were treated with 0.1 mg/kg/day intraperitoneal halofuginone injection for 30 days. The larynx specimens were examined histopathologically under light microscope for epithelization, inflammation, necrosis, and fibrosis.
  
  
  RESULTS
  The fibrosis indexes of the treated group were significantly less than those of the control group (P < .01).
  
  
  CONCLUSIONS
  Systemically applied halofuginone hydrobromide decreases fibrosis/scar tissue formation secondary to experimentally induced acute subglottic trauma.
authors.affiliation: ENT Department, GATA Haydarpasa Educational Hospital, Kadikoy, Istanbul. ertugrul@doctor.com
authors.forename: E Eylem
authors.initials: EE
authors.lastname: Ertuğrul
authors.forename: Hakan
authors.initials: H
authors.lastname: Cincik
authors.forename: Salim
authors.initials: S
authors.lastname: Dogru
authors.forename: Engin
authors.initials: E
authors.lastname: Cekin
authors.forename: Ufuk
authors.initials: U
authors.lastname: Berber
authors.forename: Atila
authors.initials: A
authors.lastname: Gungor
authors.forename: I Ethem
authors.initials: IE
authors.lastname: Poyrazoğlu
mesh_terms: D000818:Animals; D002921:Cicatrix / Q000473:pathology / Q000517:prevention & control; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005260:Female; D005355:Fibrosis; D005931:Glottis / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D007274:Injections, Intraperitoneal; D007827:Laryngitis / Q000473:pathology; D007829:Laryngostenosis / Q000473:pathology / Q000517:prevention & control; D007830:Larynx / Q000187:drug effects / Q000293:injuries* / Q000473:pathology; D008297:Male; D009336:Necrosis; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D052999:Quinazolinones / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D010880:Piperidines; D011500:Protein Synthesis Inhibitors; D052999:Quinazolinones; C010176:halofuginone